文献速递肺外科

机器人肺叶切除术与开胸术在临床I期非小细胞肺癌中的淋巴结分期升级率相似

Robotic Approach Offers Similar Nodal Upstaging to Open Lobectomy for Clinical Stage I Non-small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-03-30

该研究基于美国国家癌症数据库(NCDB)2010至2015年数据,经倾向性评分匹配比较机器人(n=7452)与开胸(n=50186)肺叶切除术治疗临床I期非小细胞肺癌(NSCLC)的淋巴结分期升级率。结论认为机器人肺叶切除术在肿瘤学结局上与开胸术等效。

要点

  • 机器人组30天和90天死亡率更低,5年总生存率相似。

核心结论

  • 机器人肺叶切除术治疗临床I期NSCLC在淋巴结分期升级率、切缘完整性和总生存方面与开胸术等效。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库(NCDB),纳入2010至2015年临床I期(≤cT2a N0 M0,AJCC第7版)接受肺叶切除术的NSCLC患者,经倾向性评分匹配机器人组(n=7452)与开胸组(n=50186),匹配后生成7452对。

关键数值与推荐

  • 淋巴结分期升级定义为意外的肺门或纵隔淋巴结受累。
  • 临床I期定义为≤cT2a N0 M0(AJCC第7版)。

临床怎么用

  • 机器人肺叶切除术可作为临床I期NSCLC开胸肺叶切除术的等效替代方案,淋巴结清扫质量与肿瘤学结局相当。
  • 机器人组检出淋巴结数更多且短期死亡率更低,支持其在早期NSCLC中的适当应用。

局限性

  • 回顾性研究设计,来自国家数据库,可能存在选择偏倚和未测量混杂因素。
  • 摘要未报告匹配后两组的具体基线特征和匹配质量指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Appropriate nodal dissection during pulmonary resection improves pathologic staging accuracy. Detection of unexpected nodal metastases can be a surrogate for nodal dissection adequacy and reflect oncologic resection quality. The goal of this study was to determine whether robotic lobectomy carries worse, same, or better incidence of nodal upstaging as open lobectomy for clinical stage I non-small cell lung cancer (NSCLC). METHODS: Data for patients with clinical stage I NSCLC (≤cT2a N0 M0, American Joint Committee on Cancer, 7th Edition) who underwent lobectomy from 2010 through 2015 were abstracted from the National Cancer Database (NCDB). Propensity score matching was performed for robotic (n = 7452) and open (n = 50,186) approaches. Primary outcomes were the number of lymph nodes examined and incidence of nodal upstaging, defined as unexpected hilar or mediastinal lymph node involvement. Secondary outcomes included resection margins and overall survival. RESULTS: Matching generated 7452 well-matched pairs. There were no differences in nodal upstaging between robotic and open procedures (820 [11.0%] vs 863 [11.6%], P = .28), despite more examined lymph nodes in the robotic group (10 vs 8, P < .001). Incidence of positive margins (145 [2.0%] vs 178 [2.4%], P = .071) was similar. The robotic group had lower 30-day (73 [1.3%] vs 105 [1.9%], P = .02) and 90-day mortality (125 [2.3%] vs 188 [3.5%], P < .001). The 5-year overall survival was similar between both groups (65.6% vs 66.7%, log-rank P = .25). CONCLUSIONS: Robotic lobectomy for clinical stage I NSCLC is an equivalent to open lobectomy as assessed by similar nodal upstaging rates, completeness of resection, and overall survival. This suggests that the robotic technology has been adopted appropriately in early-stage NSCLC.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Tang A, Raja S, Bribriesco AC, et al. Robotic Approach Offers Similar Nodal Upstaging to Open Lobectomy for Clinical Stage I Non-small Cell Lung Cancer. Ann Thorac Surg. 2020. PMID: 32240644. doi:10.1016/j.athoracsur.2020.02.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。